Linaclotide: A New Option for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation in Adults
نویسندگان
چکیده
Chronic idiopathic constipation (CC) and irritable bowel syndrome with predominant constipation (IBS-C) are the 2 most common conditions among functional gastrointestinal disorders. Despite current multiple therapeutic options, treatment remains challenging and dissatisfactory to many patients. Linaclotide is a novel therapeutic agent, which is a guanylate cyclase receptor agonist that stimulates water secretion from the intestinal epithelium by promoting chloride and bicarbonate efflux into the lumen through activation of the cystic fibrosis transmembrane conductance regulator. Clinical trials have demonstrated that linaclotide is effective, safe and well tolerated in patients with CC and IBS-C. This review article highlights the mechanism of action of linaclotide, reviews published literature based on a search of databases, including MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL), up to February 2013, and compares its utility with other currently available agents.
منابع مشابه
Linaclotide (Linzess) for Irritable Bowel syndrome With Constipation and For Chronic Idiopathic Constipation.
Linaclotide (Linzess) for irritable bowel syndrome with constipation and for chronic idiopathic constipation.
متن کاملLinaclotide: a novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome.
Chronic constipation and irritable bowel syndrome (IBS) are functional gastrointestinal disorders that significantly affect patients' quality of life. Chronic constipation and IBS are prevalent-1 2% of the US population meet the diagnostic criteria for IBS, and 1 5% meet the criteria for chronic constipation- and these conditions negatively impact the healthcare system from an economic perspect...
متن کاملLinaclotide for irritable bowel syndrome with constipation: a review
2015 Irritable bowel syndrome (IBS) is a common disorder that poses a management challenge. IBS with constipation as the dominant bowel habit is a common phenotype and features abdominal pain, infrequent bowel movements or difficult defecation, bloating and distention, as major symptoms. While laxatives increase stool frequency, they have little impact on other symptoms; prior, more specificall...
متن کاملPersistent constipation and abdominal adverse events with newer treatments for constipation
BACKGROUND Clinical trials of several new treatments for opioid-induced constipation (OIC), chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C) have focused on differences between subjects relieved of constipation with placebo and active treatment. Patients and clinicians however, are more interested in the probability these treatments provide act...
متن کاملReview article: linaclotide for the management of irritable bowel syndrome with constipation
BACKGROUND Irritable bowel syndrome with constipation (IBS-C) represents a significant burden to patients and healthcare systems due to its prevalence and lack of successful symptomatic resolution with established treatment options. Linaclotide 290 μg has recently been approved by the European Medicines Agency (EMA) for moderate-to-severe IBS-C and by the US Food and Drug Administration for IBS...
متن کامل